N/A N=54 Postoperative Virtual Clinical Encounters
Pelvic Organ Prolapse
Primary: Patient Satisfaction Via the Patient Satisfaction Questionnaire -18 — 80.7; 81.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Phase 3 N=311 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
Migraine
Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 54; 56; 54; 61 participants
Phase 2 N=56 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Contact Dermatitis
Primary: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration — 4; 0; 0; 2 Participants
Phase 3 N=62 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
Pediatric Immuno-Tolerant Chronic Hepatitis B
Primary: Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation — 3.8; 0 Percentage of…
Phase 3 N=498 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
Axial Psoratic Arthritis
Primary: Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 — 66.3; 62.9; 31.2 percentage of participants…
Phase 4 N=14 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 5; 24 PRU — p=<0.05
Phase 2 N=79 Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05
Alzheimer's Disease
Primary: Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status — 0.0205; -0.0912; 0.0352; -0.0124 standardized uptake value ratio (SUVr) — p=0.0166
N/A N=150 Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer
Postoperative Nausea and Vomiting
Primary: Postoperative Nausea (Numeric Rating Scale for Nausea) — 0; 0; 0 scores on a scale
N/A N=35 Cardiac MRI for Metal on Metal Hip Resurfacing
Cardiomyopathy
Primary: Cardiac Ejection Fraction — 64; 66; 65; 62 Percent
N/A N=4 Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness
Traumatic Brain Injury
Primary: Intensity of Adverse Event — 0.5; 0.98; 0.33 score on a scale — p=<0.05
Phase 2 N=161 Tau Screening Study in Subjects With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 51; 13; 1; 65 Participants
Phase 2 N=155 Tau Screening Study in Patients With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 56; 22; 78; 2 Participants
Phase 3 N=1,617 Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
ASCVD · Risk Factor, Cardiovascular · Elevated Cholesterol
Primary: Percentage Change in LDL-C From Baseline to Day 510 — -49.3; 4.2 Percent change — p=<0.0001
N/A N=108 In-Stent Restenosis Post-Approval Study
Peripheral Artery Disease · Vascular Disease
Primary: Primary Effectiveness — 0.715 Probability